Court Favors Cardium In Gene Therapy Patent Dispute

Law360, New York (May 11, 2006, 12:00 AM EDT) -- The U.S. Court of Appeals for the Federal Circuit has ruled that Arch Development Corp. and Arch’s licensee, Boston Scientific Corp. will not be able to assert patents relating to a gene therapy approach designed to go above and beyond stents for the treatment of heart disease.

Giving medical technology company Cardium Therapeutics Inc. exclusive control over patents dealing with angiogenic treatments in the United States, the Federal Circuit affirmed an earlier ruling by the Board of Patent Appeals and Interferences (BPAI) that Arch and Boston...
To view the full article, register now.